Clinical characterization and molecular mechanisms of statin myopathy

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 7, 2008, Pages 955-969

  Toth, Peter P ^a,b   Harper, Charles R ^c   Jacobson, Terry A ^d  

^a Sterling Rock Falls Clinic Ltd ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Apoptosis; Atrogin 1; Coenzyme Q10; Creatine kinase; Myalgia; Myopathy; Rhabdomyolysis; Statin; Ubiquitin proteasome pathway

Indexed keywords

AGGRESTAT; ALPHA TOCOPHEROL; AMIODARONE; ATORVASTATIN; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CYCLOSPORIN A; DICLOFENAC; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; METHOTREXATE; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PREDNISOLONE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; TOLBUTAMIDE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY ACID OXIDATION; GENE EXPRESSION; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIPOPHILICITY; LOW DRUG DOSE; LUPUS VULGARIS; MONOTHERAPY; MUSCLE CELL; MUSCLE METABOLISM; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NEUROMUSCULAR DISEASE; NONHUMAN; PATHOGENESIS; POLYMYOSITIS; PRIMARY PREVENTION; PROTEIN DEGRADATION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TOXIC MYOPATHY; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; MUSCLE DISEASE; PATHOPHYSIOLOGY;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RISK FACTORS;

EID: 52049116959     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.7.955     Document Type: Review

References (66)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
2. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149-1158 (2003).
3. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107(17), 2185-2189 (2003).
4. Maggini M, Rascherd R, Traversa G et al. The cerivastatin withdrawal crisis: a "post-mortem analysis. Health Policy 69(2), 151-157 (2004).
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33(9), 2337-2341 (2002).
6. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 97(8A), 89C-94C (2006).
7. Law M, Rudnicka AR. Statin safety: a systematic review. Am. J. Cardiol. 97(8A), 52C-60C (2006).
8. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12(5), 565-569 (2001).
9. Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy 25(3), 345-351 (2005).
10. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO Study. Cardiovasc. Drugs Ther. 19(6), 403-414 (2005).
11. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. NZ Med J. 104(924), 493-495 (1991).
12. Kordas KC, Phillips PS, Golomb BA. Clinical characteristics of 1053 patients with statin-associated muscle complaints. Arterioscler. Thromb. Vasc. Biol. 24, e133 (2004).
13. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med. 165(22), 2671-2676 (2005).
14. Rosenson RS. Current overview of statin-induced myopathy. Am J. Med. 116(6), 408-416 (2004).
15. Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerv. 34(2), 153-162 (2006).
16. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92(4B), 23K-29K (2003).
17. Prueksaritanont T, Tang C, Qiu. Y, Mu, L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30(11), 1280-1287 (2002).
18. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95(1), 120-122 (2005).
19. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 27452), 37161-37168 (1999).
20. Nishizato Y Ieiri I, Suzuki H et al. Prolymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73(6), 554-565 (2003).
21. Bottorff MB. Statin safety and drug interactions: clinical implications. Am. J. Cardiol. 97(8A), 27C-31C (2006).
22. Davidson MH, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol. 49(17), 1753-1762 (2007).
23. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arck Intern Med. 163(5), 553-564 (2003).
24. Harper CR, Jacobson TA. Managing dyslipidemia in the CKD patient. J. Am. Coll. Cardiol. (2008) (In Press).
25. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis. An evaluation of 475 hospitalized patients. Medicine. 84(6), 377-385 (2005).
26. Phillips PS, Haas RH. Observations from a statin myopathy clinic. Arch. Intern. Med. 166(11), 1232-1233 (2006).
27. Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137(7), 581-585 (2002).
28. Guijarro C, Blanco-Colio LM, Ortego M et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83(5), 490-500 (1998).
29. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 289(13), 1681-1690 (2003).
30. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18(4), 401-408 (2007).
31. Mach F. Statins as immunomodulatory agents. Circulation 109(21 Suppl. 11), 15-17 (2004).
32. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun. Rev. 2(6), 332-338 (2003).
33. Sadeghi MM, Tiglio A, Sadigh K et al. Inhibition of interferon-gamma mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71(9),I262-1268 (2001).
34. Needham M, Fabian V, Knezevic W. Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-1 associated with statin therapy. Neuromuscul. Disord. 17(2), 194-200 (2007).
35. Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler. Thromb. Vasc. Biol. 25(12), 2441-2444 (2005).
36. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Atheroscler. Tbromb. Vasc. Biol 25(12), 2560-2566 (2005).
37. Hanai J, Cao P, Tanksale P et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest. 117(12), 3940-3951 (2007).
38. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 6(7), (2007).
39. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 117(1)1, 183-188 (2004).
40. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr. Opin. Rheumatol. 19(1), 67-73 (2007).
41. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J. Am. Coll. Cardiol. 49(23), 2231-2237 (2007).
42. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 7(Suppl.), S168-SI74 (2007).
43. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am. J. Cardiol. 99(10), 1409-1412 (2007).
44. Paiva H, Thelen KM, VanCoster R et al. High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial. Clin. Pharmacol. Ther. 78(1), 60-68 (2005).
45. Laaksonen R, Jokelainen K, Sahi Tikkanen MJ, Himsberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in himans. Clin. Pharmacol. Ther. 57(1), 62-66 (1995).
46. Langsjoen PH, Langsjoen AM. Coenzyme Q10 in CVD with emphases on heart failure and myocardial ischaemia. Asia Pacific Heart J. 7(3), 160-168 (1998).
47. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion 7(Suppl.), S154-S167 (2007).
48. Crane FL. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 20(6), 591-598 (2001).
49. Horvath R, Schneiderat P, Schoser BG et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 66(2), 253-255 (2006).
50. Thibault A, Samid D, Tompkins AC et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2(3), 483-491 (1996).
51. Young JM, Florkowski CM, Molyneux SL et al. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgias. Am. J. Cardiol. 100(9), 1400-1403 (2007).
52. Mastaglia FL. Drug induced myopathies. Practical Neurology 6(1), 4-13 (2006).
53. Beetham R, Biochemical investigation of suspected rhabdomyolysis. Ann. Clin. Biochem. 37(Pt 5), 581-587 (2000).
54. Kearns AK, Bilbie CL, Clarkson PM et al. The creatine kiriase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis (2008) (Epub ahead of print).
55. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol. 145(1), 91-98 (1997).
56. Baker SK. Molecular clues into the pathogenesis of statin-mediated toxicity. Muscle Nerve 31(5), 572-580 (2005).
57. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307-1316 (2004).
58. Alsheikh-Ali AA, Maddukuri PV, Han H, Kaxas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J. Am. Coll. Cardiol. 50(5), 409-418 (2007).
59. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safity of atorvascatin initiated at different starting doses in patients with dyslipidemia. Am. Heart J. 149(1), e1-e8 (2005).
60. Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am. J. Cardiol. 97(8-A), 69C-76C (2006).
61. Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review- rhabdomyolysis - an overview for clinicians. Crit. Care 9(2), 158-169 (2005).
62. Stein EA, Ballantyne CM, Windier E et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone and the combination of fluvastatin XL 80 mg with ezetimibe, in patients with a history of muscle-related side effects with other statins. Am. J. Cardiol. 101 (4), 490-496 (2008).
63. Havranek JM, Woffsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy. Am. J. Med. 119(3), 285-286 (2006).
64. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am. J. Med. 99(6A), 47C-55C (2007).
65. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99(6A), 3C-18C (2007).
66. Jacobson TA. Toward pain-free statin prescribing: a clinical algorithm for diagnosis and management of myalgia. 83(6), 687-700 (2008).